InvestorsHub Logo
Followers 483
Posts 61192
Boards Moderated 17
Alias Born 09/20/2001

Re: Joseph_K post# 455950

Friday, 04/05/2024 5:51:24 PM

Friday, April 05, 2024 5:51:24 PM

Post# of 464812
Please elucidate on this point..

"MacFarlane's presentation would have raised red flags. Specifically, for the type of endpoints in those trials, Odds Ratio was a very peculiar choice, especially since there were no numbers reported about how many of the trial subjects crossed the threshold used for calculating the Odds Ratios. The reddest flag of all was the failure to include a comparison of the means for the ADCS-ADL endpoint. I believe these are the reasons Doc328, for example, sold his shares. Furthermore, the December 5 conference call was pathetic and did not confront the doubts raised by critics, including Feuerstein. I think Feuerstein is a schmuck, but not all his criticisms of the top-line results release, IIRC, were bull."

I encourage others to re-read and discuss the points you made in the replied to post. It is balanced, with a lot of food for thought.

I believe you and I would make ideal lead plaintiffs in a securities suit based on the CTAD presentation, but I'm not going to volunteer to do that. I wish the lawsuits would just disappear. (BTW, in contrast, I see no basis for a lawsuit based on the Rett results and PRs.)

I also want to include here, that I think Anavex's shot at approval is better than at any previous time since I've been involved. The combination of "Kun Jin's <0.025 p-value finesse," the recent biomarker results such as regarding brain volume, and the FDA's draft guidance negating the import of the ADCS-ADL endpoint, seems to me to make the P2b/3 trial results an excellent basis for approval. I wish, of course, that I'd sold on December 2 or 5, and that I were doing my AVXL purchasing now. I've sold over half my shares, very belatedly and at a big loss, but I still have a substantial amount. If I didn't already own "enough," I would now, in light of what I said earlier in this paragraph, be buying more.



We need a world where medicine's priority is to make people better..... Not make money for stockholders which are increasingly defined as hedge funds and institutional interests who have PROFIT as their primary goal. Such institutions face a conflict of interest...

The following quote is hypothetical:

Gee, if people have an effective treatment for CNS diseases they wont buy as much of the ... (shit that we already control) and we'll loose money.



This article will give you a hint of the $$$$$$$$$$$$ involved..


https://www.linkedin.com/pulse/central-nervous-system-cns-therapeutics-market-report-priya-tripathi-dafqc/?trk=article-ssr-frontend-pulse_more-articles_related-content-card

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News